Regulus Therapeutics (RGLS)
(Delayed Data from NSDQ)
$1.55 USD
-0.10 (-5.78%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $1.54 -0.01 (-0.65%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth D Momentum F VGM
Key Expected Earnings Data
Report Date | Period Ending | Zacks Consensus Estimate | Earnings ESP |
---|---|---|---|
11/14/2024
Time: -- |
9/2024 | $-0.18 | 0.00% |
Earnings Summary
For their last quarter, Regulus Therapeutics (RGLS) reported earnings of -$0.17 per share, in line with the Zacks Consensus Estimate. This reflects a breakeven earnings surprise. Look out for RGLS's next earnings release expected on November 14, 2024. For the next earning release, we expect the company to report earnings of -$0.18 per share, reflecting a year-over-year increase of 55%.
Earnings History
Price & Consensus
Zacks News for RGLS
Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study
RGLS: What are Zacks experts saying now?
Zacks Private Portfolio Services